We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Rapid Urine Test Speeds Antibiotic Selection for UTIs

By LabMedica International staff writers
Posted on 31 Mar 2026

Urinary tract infections are a common reason for antibiotic prescribing and have led to more than 800,000 hospital admissions across England in the past five years, according to National Health Service data. More...

Conventional urine culture and antibiotic susceptibility testing can take two to three days, during which empiric therapy may be mismatched, while resistance is present in about a quarter of samples. To address these delays and improve treatment accuracy, researchers have developed a direct-from-urine test that identifies an effective antibiotic in hours rather than days.

University of Reading investigators, working with the University of Southampton and Hampshire Hospitals NHS Foundation Trust, demonstrated a rapid method that determines which antibiotic will work in an average of 5.85 hours. The National Institute for Health and Care Research (NIHR)‑funded study was published on March 31, 2026, in the Journal of Antimicrobial Chemotherapy. Standard laboratory testing typically requires two to three days, highlighting the potential time savings reported

The technology eliminates the need for an overnight culture step. After simple sample processing, a cartridge containing fine tubes preloaded with different antibiotics is placed directly into the urine specimen and inserted into an instrument. Optical imaging then monitors bacterial growth in each tube; inhibited growth indicates susceptibility, while continued growth signals resistance, enabling results in under six hours.

Accuracy was assessed using 352 urine samples already collected for routine testing at Basingstoke and North Hampshire Hospital, showing 96.95% agreement with the reference method across seven first‑line antibiotics for treating UTI. A second study used 90 fresh emergency department samples split into duplicates, with boric acid preservative added to one of each pair, and demonstrated 98.75% agreement for direct‑from‑urine testing.

According to the authors, this is the first study to directly compare urine samples with and without boric acid to assess the preservative’s impact on a rapid direct‑from‑urine approach. The work marks an important milestone for Astratus Limited, a University of Reading spin‑out founded in November 2024 by the research team behind the test. 

“By the time the laboratory delivers the result under current methods, a patient may already have finished their antibiotics, or been given ones that do not work. Being able to tell a doctor the same day which antibiotic to use means the patient gets the right treatment sooner, reducing the risk of resistance developing and their infection turning into potentially lethal sepsis,” said Dr. Oliver Hancox, Chief Executive Officer of Astratus Limited.

Related Links
University of Reading


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Electrolyte Analyzer
CBS-4000 (CBS-400)
New
Prefilled Tubes
Prefilled 5.0ml Tubes
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.